Castration-Resistant Prostate Carcinoma (DBCOND0086843)

Identifiers

Synonyms
Castrate Resistance Prostate Cancer / Castration Resistant Prostate Cancer (CRPC) / Castrate Resistant Prostate Cancer (CRPC) / Castrate Resistant Prostate Cancer / Prostate Cancer (CRPC) / Castration-Resistant Prostate Cancer / Castration resistant / Castrate Resistent Prostate Cancer / Castrate-Resistant Prostate Cancer / Castrate-resistant Prostate Cancer (CRPC) / Castration-Resistant Prostate Cancer (CRPC) / Prostate Cancer Castration-resistant Prostate Cancer / Castration Resistant Prostate Cancer / Castration Resistant Prostate Cancer, CRPC / Castration-Resistant / Hormone-refractory prostate cancer / Hormone refractory prostate cancer (disorder)

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT03218826
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgerytreatment1active_not_recruiting
NCT03419234
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxeltreatment2active_not_recruiting
NCT04071236
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapytreatment1 / 2recruiting
NCT06236139
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancertreatment1 / 2recruiting
NCT06470243
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Bodytreatment3recruiting
NCT04550494
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variationstreatment2recruiting
NCT04592237
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancertreatment2active_not_recruiting
NCT04754425
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancertreatment2active_not_recruiting
NCT03204812
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancertreatment2completed
NCT03517969
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancertreatment2active_not_recruiting
NCT04716725
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancerdiagnostic2active_not_recruiting
NCT06616155
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancertreatment1 / 2not_yet_recruiting
NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVtreatment1active_not_recruiting
NCT06632977
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trialtreatment2not_yet_recruiting
NCT06039371
Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Studytreatment2recruiting
NCT05805371
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate CancerNo drug interventionstreatment1recruiting
NCT06145633
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancertreatment2recruiting
NCT06305598
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancertreatment1recruiting
NCT02099864
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapytreatment2active_not_recruiting
NCT03360721
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancertreatment2active_not_recruiting
NCT03873805
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancertreatment1active_not_recruiting
NCT04777071
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancerdiagnostic2recruiting
NCT05960578
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Studytreatment2recruiting
NCT03999515
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancertreatment2terminated
NCT05113537
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancertreatment1 / 2recruiting
NCT06526299
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Diseasetreatment2not_yet_recruiting
NCT03751436
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancertreatment1completed
NCT06288113
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trialtreatment2recruiting
NCT02893917
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancertreatment2active_not_recruiting
NCT04159896
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancertreatment2terminated
NCT05547386
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancertreatment3completed
NCT02312557
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamidetreatment2active_not_recruiting
NCT05807126
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutationstreatment1withdrawn
NCT02228265
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving EnzalutamideNot AvailableNot Availablecompleted
NCT03805594
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancertreatment1active_not_recruiting
NCT02555189
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expressiontreatment1 / 2completed
NCT04951492
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinomatreatment2terminated
NCT03503344
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancertreatment2active_not_recruiting
NCT01881867
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancertreatment2completed
NCT01576172
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancertreatment2completed
NCT01505868
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancertreatment1 / 2completed
NCT03516812
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancertreatment2completed
NCT05730712
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancertreatment2recruiting
NCT02598895
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathwaytreatment2completed
NCT04455750
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapytreatment3active_not_recruiting
NCT02703623
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancertreatment2active_not_recruiting
NCT06200103
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancertreatment2recruiting
NCT05689021
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutationstreatment2recruiting
NCT05398302
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand TherapyNo drug interventionsdiagnostic1recruiting
NCT04693377
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialNo drug interventionssupportive_careNot Availablerecruiting
NCT04616547
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to BonesNo drug interventionstreatment2terminated
NCT03217747
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignanciestreatment1 / 2active_not_recruiting
NCT04279561
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancerdiagnostic1terminated
NCT03344211
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancertreatment2active_not_recruiting
NCT05479578
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancertreatment1recruiting
NCT03517488
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumorstreatment1completed
NCT03442556
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiencytreatment2active_not_recruiting
NCT02522715
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancertreatment1 / 2active_not_recruiting
NCT04033432
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancertreatment2unknown_status
NCT04388852
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancerstreatment1recruiting
NCT05037500
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancertreatment1recruiting
NCT03582475
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostatetreatment1completed
NCT05168618
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trialtreatment2recruiting
NCT04489719
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate CancerNot AvailableNot Availablerecruiting
NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trialtreatment1terminated
NCT03448458
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancerdiagnostic2completed
NCT03406858
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancertreatment2completed
NCT04927663
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor ExpressionNo drug interventionsdiagnostic1recruiting
NCT04471974
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancertreatment2recruiting
NCT03317392
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasistreatment1 / 2active_not_recruiting
NCT02565901
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancertreatment1 / 2terminated
NCT03456804
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancertreatment2completed
NCT05924672
Efficacy of Ra-223 in PSMA PET Optimally Selected Patientstreatment2not_yet_recruiting
NCT03596710
Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand TherapyNo drug interventionsdiagnosticNot Availablewithdrawn
NCT02532114
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancertreatment1completed
NCT03709550
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancertreatment1 / 2withdrawn